Baker Norton Pharmaceuticals, Inc.

Baker Cummins Pharmaceuticals, Inc.

Andrx Labs, LLC

Other

Andrx Pharmaceuticals, Inc.

Elliot F Hahn

Phillip Frost

Jack Fishman

Chih-Ming Chen

Fred P Sherman

Hillel Glover

Jay S Skyler

Jing J Lu

Jainbo Xie

Jane Chang Chen

Gregory A Smith

Disclosed and described is a novel dose titration procedure for administering the opioid antagonist, nalmefene, to a patient diagnosed with post-traumatic stress disorder (PTSD).

Method for treating post-traumatic stress disorder

A pharmaceutical dosage form comprising a controlled release component comprising an antihyperglycemic drug in combination with a second component comprising a angiotensin antagonist is herein disclosed and described.

Pharmaceutical formulation containing a biguanide and an angiotensin antagonist

The invention provides a controlled release pharmaceutical unit dose composition for oral administration which comprises: (a) an internal phase which comprises captopril or a prodrug of captopril in admixture with a hydrogel forming agent; and (b) an external phase which comprises a coating which resists dissolution in the stomach.

Controlled release formulation of captopril or a prodrug of captopril

A method of treating human or animal patients suffering from insulin resistance syndromes, particularly diabetes mellitus, by administering an effective amount of the compound magnesium vanadate. Daily dosage ranges are preferably from about 2 to about 60 mg per kg of patient body weight. Pharmaceutical compositions for use in the method of treatment include magnesium vanadate and at least one pharmaceutically acceptable inert ingredient, and may be oral, parenteral, transdermal or transmucosal dosage forms containing from about 50 to about 1000 mg of magnesium vanadate per unit.

Method and composition for treatment of insulin resistance syndromes

Novel anti-viral compounds comprise phosphate-linked dimers of anti-viral nucleoside derivatives, or salts or esters of such nucleoside dimers. Pharmaceutical compositions containing the dimers and methods of treatment utilizing the same are disclosed.

Anti-viral compounds, dosage forms and methods

Aldosterone biosynthesis inhibitors having substantially no intrinsic antiandrogenic activity are disclosed as well as pharmaceutical compositions containing such compounds and methods of treatment utilizing these compositions.

Aldosterone biosynthesis inhibitor

A method of treating a patient suffering from multiple sclerosis comprising daily administration to such patient of from about 1 to about 100 mg of a pure narcotic antagonist, e.g., nalmefene or naltrexone. The antagonist may be administered in divided doses from one to four times daily, preferably by the oral route. Parenteral, transmucosal and transdermal administration may be utilized where suitable.

Growing community of inventors

North Miami Beach, FL, United States of America

Elliot F Hahn